The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Changes in the use of eythropoetin-stimulating agents (ESAs) in cancer patients: Before and after FDA safety advisories.
Dana Stafkey-Mailey
No relevant relationships to disclose
Mike Dickson
No relevant relationships to disclose
LeAnn B. Norris
No relevant relationships to disclose
Charles L. Bennett
No relevant relationships to disclose